Commodore Capital’s Kura Oncology KURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,800,000
Closed -$35.2M 37
2024
Q3
$35.2M Buy
1,800,000
+206,650
+13% +$4.19M 2.2% 17
2024
Q2
$32.8M Buy
1,593,350
+68,350
+4% +$1.4M 2.24% 18
2024
Q1
$32.5M Buy
1,525,000
+276,938
+22% +$5.38M 2.18% 18
2023
Q4
$17.9M Sell
1,248,062
-151,938
-11% -$1.49M 1.57% 23
2023
Q3
$12.8M Hold
1,400,000
1.49% 22
2023
Q2
$14.8M Buy
1,400,000
+195,042
+16% +$2.31M 1.66% 20
2023
Q1
$14.7M Buy
1,204,958
+105,551
+10% +$1.32M 2.24% 16
2022
Q4
$13.6M Buy
1,099,407
+200,000
+22% +$2.91M 2.06% 19
2022
Q3
$12.3M Sell
899,407
-927,084
-51% -$14.3M 1.98% 17
2022
Q2
$33.5M Buy
1,826,491
+1,049,977
+135% +$15.1M 7.08% 7
2022
Q1
$12.5M Buy
+776,514
New +$11.2M 2.79% 14
2021
Q4
Sell
-999,433
Closed -$18.7M 29
2021
Q3
$18.7M Buy
999,433
+377,940
+61% +$7.12M 4.94% 6
2021
Q2
$13M Buy
621,493
+99,938
+19% +$2.48M 4.51% 8
2021
Q1
$14.7M Buy
521,555
+388,052
+291% +$12.3M 5.87% 3
2020
Q4
$4.36M Buy
+133,503
New +$4.69M 2.37% 19

Other funds holding KURA

Commodore Capital's KURA Position: Q4 2024 in Review

Commodore Capital sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 1,800,000 shares — an estimated $35.2M sold.

Commodore Capital first reported a position in KURA in Q4 2020 and held it in 15 quarters. The position peaked at $35.2M in Q3 2024. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

  • Commodore Capital reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
  • Commodore Capital sold 1,800,000 Kura Oncology shares in Q4 2024, an estimated $35.2M.
  • Commodore Capital first reported a position in Kura Oncology in Q4 2020 and held it in 15 quarters.
  • Commodore Capital's Kura Oncology position peaked at $35.2M in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.